Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-08
Amanda J. Stolarz
Federal Grant PI
Assistant Professor
Also affiliated: The University of Texas MD Anderson Cancer Center (2019); University of Arkansas Medical Center (2015); Reprogenetics (2022); Theriva Biologics (United States) (2022); The University of Texas Medical Branch at Galveston (2019)
Pharmaceutical Science, College of Pharmacy
10 h-index
29 pubs
298 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Amanda J. Stolarz's research focuses on understanding and mitigating drug-induced lymphatic dysfunction and lymphedema. She investigates the mechanisms by which certain chemotherapies, such as doxorubicin, disrupt lymphatic vessel function, leading to fluid accumulation and swelling. Her work utilizes animal models, specifically rats, to evaluate the efficacy of potential therapeutic interventions. A significant area of her investigation involves the role of ryanodine receptors as therapeutic targets to prevent or reverse doxorubicin-induced lymphatic damage. This research is supported by a $368,387 grant from the NIH/National Cancer Institute, with Stolarz serving as the Principal Investigator.
Beyond her work on drug-induced lymphedema, Stolarz also explores broader aspects of vascular health and cellular mechanisms. Her publications address the role of PCSK9 in endothelial cell efferocytosis and vascular aging, as well as the potential of endothelial cells to function as macrophage-like gatekeepers. She has also investigated liposome formulations for tumor-targeted drug delivery in conjunction with radiation therapy. Stolarz leads a research group at the University of Arkansas for Medical Sciences, where she collaborates with several colleagues, including Soumiya Pal, Nancy J. Rusch, Ashim K. Bagchi, and Shengyu Mu, with whom she has co-authored multiple publications.
Metrics
- h-index: 10
- Publications: 29
- Citations: 298
Positions
-
Assistant Professor 2018–presentUniversity of Arkansas for Medical Sciences Pharmaceutical Science, College of Pharmacy Institutional directory
Selected Publications
-
Abstract LB219: Proteomic signatures of doxorubicin-induced lymphatic dysfunction in tumor-bearing rats (2026)
-
Smooth muscle excitability (2025)
-
Clinical Relevance of Animal Models of Lymphatic Dysfunction and Lymphedema (2025)
-
Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats (2024)
-
Proteomics Approach to Identify Anthracycline-induced Cardiotoxicity Mechanisms in Human Cardiac Fibroblasts (2024)
-
JoVE Video Dataset (2024)
-
Real-Time Evaluation of Absolute, Cytosolic, Free Ca2+ and Corresponding Contractility in Isolated, Pressurized Lymph Vessels (2024)
-
PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging (2023)
-
Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy (2022)
-
Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy (2022)
-
Opinion: Endothelial Cells - Macrophage-Like Gatekeepers? (2022)
-
Hypertension Induces Contractile Dysfunction in Rat Mesenteric Lymph Vessels (2022)
-
Drug-Related Lymphedema: Mysteries, Mechanisms, and Potential Therapies (2022)
-
Dantrolene Prevents the Lymphostasis Caused by Doxorubicin in the Rat Mesenteric Circulation (2021)
-
Mechanisms of Increased Infarct Volume in a Rat Model of Ischemic Stroke: Implications for Leptomeningeal Collateral Artery Function and Beta Blocker Therapy (2021)
Federal Grants 1 $364,698 total
NIH
Contact PI
Aug 2023 - Jul 2028
Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction
Grants & Funding
As listed on this researcher's institutional profile. Federal awards with verified records are shown above.
- Doxorubicin suppression of lymphatic function and therapeutic reversal NIH Co-Investigator
- Center for Studies of Host Response to Cancer Therapy NIH Co-Investigator
Collaboration Network
Top Collaborators
Nancy J. Rusch
University of Arkansas for Medical Sciences
17 shared publications
In database
- PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging
- Gender Differences in Cardiovascular Drugs
- Doxorubicin Activates Ryanodine Receptors in Rat Lymphatic Muscle Cells to Attenuate Rhythmic Contractions and Lymph Flow
- Drug-Related Lymphedema: Mysteries, Mechanisms, and Potential Therapies
- Dantrolene Prevents the Lymphostasis Caused by Doxorubicin in the Rat Mesenteric Circulation
Showing 5 of 17 shared publications
Terry W. Fletcher
University of Arkansas for Medical Sciences
7 shared publications
In database
- Doxorubicin Activates Ryanodine Receptors in Rat Lymphatic Muscle Cells to Attenuate Rhythmic Contractions and Lymph Flow
- High‐speed microscopy for in vivo monitoring of lymph dynamics
- Characterization of a surgical model of lymphatic insufficiency in the rat mesentery
- Doxorubicin Inhibition of Lymphatic Function is Mediated by Ryanodine Receptors and Prevented by Dantrolene
- Doxorubicin inhibits lymphatic function in vitro and in vivo (655.1)
Showing 5 of 7 shared publications
Soumiya Pal
University of Arkansas for Medical Sciences
7 shared publications
In database
- Drug-Related Lymphedema: Mysteries, Mechanisms, and Potential Therapies
- Dantrolene Prevents the Lymphostasis Caused by Doxorubicin in the Rat Mesenteric Circulation
- Clinical Relevance of Animal Models of Lymphatic Dysfunction and Lymphedema
- Real-Time Evaluation of Absolute, Cytosolic, Free Ca2+ and Corresponding Contractility in Isolated, Pressurized Lymph Vessels
- Hypertension Induces Contractile Dysfunction in Rat Mesenteric Lymph Vessels
Showing 5 of 7 shared publications
Ekaterina I. Galanzha
University of Arkansas for Medical Sciences
6 shared publications
In database
- Doxorubicin Activates Ryanodine Receptors in Rat Lymphatic Muscle Cells to Attenuate Rhythmic Contractions and Lymph Flow
- High‐speed microscopy for in vivo monitoring of lymph dynamics
- Characterization of a surgical model of lymphatic insufficiency in the rat mesentery
- Doxorubicin Inhibition of Lymphatic Function is Mediated by Ryanodine Receptors and Prevented by Dantrolene
- Doxorubicin inhibits lymphatic function in vitro and in vivo (655.1)
Showing 5 of 6 shared publications
Brittney R. Garner
University of Arkansas for Medical Sciences
6 shared publications
In database
- Dantrolene Prevents the Lymphostasis Caused by Doxorubicin in the Rat Mesenteric Circulation
- KATP Channel Openers Inhibit Lymphatic Contractions and Lymph Flow as a Possible Mechanism of Peripheral Edema
- High‐speed microscopy for in vivo monitoring of lymph dynamics
- Contribution of the Renal Lymphatic Circulation to the Development of Salt‐Sensitive Hypertension
- Characterization of a surgical model of lymphatic insufficiency in the rat mesentery
Showing 5 of 6 shared publications
Shengyu Mu
University of Arkansas for Medical Sciences
6 shared publications
In database
- Drug-Related Lymphedema: Mysteries, Mechanisms, and Potential Therapies
- Dantrolene Prevents the Lymphostasis Caused by Doxorubicin in the Rat Mesenteric Circulation
- Opinion: Endothelial Cells - Macrophage-Like Gatekeepers?
- KATP Channel Openers Inhibit Lymphatic Contractions and Lymph Flow as a Possible Mechanism of Peripheral Edema
- Contribution of the Renal Lymphatic Circulation to the Development of Salt‐Sensitive Hypertension
Showing 5 of 6 shared publications
Vladimir P. Zharov
University of Arkansas for Medical Sciences
5 shared publications
In database
- Doxorubicin Activates Ryanodine Receptors in Rat Lymphatic Muscle Cells to Attenuate Rhythmic Contractions and Lymph Flow
- High‐speed microscopy for in vivo monitoring of lymph dynamics
- Characterization of a surgical model of lymphatic insufficiency in the rat mesentery
- Doxorubicin Inhibition of Lymphatic Function is Mediated by Ryanodine Receptors and Prevented by Dantrolene
- Doxorubicin Acutely Inhibits Lymph Flow in Rat Mesenteric Lymph Vessels
Mustafa Sarimollaoglu
University of Arkansas for Medical Sciences
5 shared publications
In database
- Doxorubicin Activates Ryanodine Receptors in Rat Lymphatic Muscle Cells to Attenuate Rhythmic Contractions and Lymph Flow
- KATP Channel Openers Inhibit Lymphatic Contractions and Lymph Flow as a Possible Mechanism of Peripheral Edema
- High‐speed microscopy for in vivo monitoring of lymph dynamics
- Characterization of a surgical model of lymphatic insufficiency in the rat mesentery
- Doxorubicin Acutely Inhibits Lymph Flow in Rat Mesenteric Lymph Vessels
Sung W. Rhee
Kaiser Permanente
4 shared publications
In database
- Doxorubicin Activates Ryanodine Receptors in Rat Lymphatic Muscle Cells to Attenuate Rhythmic Contractions and Lymph Flow
- Mechanisms of Increased Infarct Volume in a Rat Model of Ischemic Stroke: Implications for Leptomeningeal Collateral Artery Function and Beta Blocker Therapy
- Hypertension Induces Contractile Dysfunction in Rat Mesenteric Lymph Vessels
- Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats
Ashim K. Bagchi
University of Arkansas for Medical Sciences
4 shared publications
In database
- Real-Time Evaluation of Absolute, Cytosolic, Free Ca2+ and Corresponding Contractility in Isolated, Pressurized Lymph Vessels
- JoVE Video Dataset
- Proteomics Approach to Identify Anthracycline-induced Cardiotoxicity Mechanisms in Human Cardiac Fibroblasts
- Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats
David S. Henry
University of Arkansas for Medical Sciences
3 shared publications
In database
- Mechanisms of Increased Infarct Volume in a Rat Model of Ischemic Stroke: Implications for Leptomeningeal Collateral Artery Function and Beta Blocker Therapy
- Hypertension Induces Contractile Dysfunction in Rat Mesenteric Lymph Vessels
- Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats
Asif R. Pathan
University of Arkansas for Medical Sciences (US)
2 shared publications
- Doxorubicin Inhibition of Lymphatic Function is Mediated by Ryanodine Receptors and Prevented by Dantrolene
- Doxorubicin inhibits lymphatic function in vitro and in vivo (655.1)
Rachel Versluis
University of Arkansas for Medical Sciences (US)
2 shared publications
- Doxorubicin Inhibition of Lymphatic Function is Mediated by Ryanodine Receptors and Prevented by Dantrolene
- Doxorubicin inhibits lymphatic function in vitro and in vivo (655.1)
Joseph R. Stimers
University of Arkansas for Medical Sciences (US)
2 shared publications
- Doxorubicin Inhibition of Lymphatic Function is Mediated by Ryanodine Receptors and Prevented by Dantrolene
- Doxorubicin inhibits lymphatic function in vitro and in vivo (655.1)
John C. Marecki
University of Arkansas for Medical Sciences
2 shared publications
In database
- Doxorubicin Activates Ryanodine Receptors in Rat Lymphatic Muscle Cells to Attenuate Rhythmic Contractions and Lymph Flow
- Doxorubicin Acutely Inhibits Lymph Flow in Rat Mesenteric Lymph Vessels
Similar Researchers
Based on overlapping research topics
Kate Steed
University of Arkansas for Medical Sciences
Disease Mechanisms Research
Pharmacological Effects and Toxicity Studies
Cardiovascular Function and Risk Factors
J.C. Hsu
University of Arkansas for Medical Sciences
Drug-Induced Hepatotoxicity and Protection
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
Koichiro Nagano
University of Arkansas for Medical Sciences
Disease Mechanisms Research
Pharmacological Effects and Toxicity Studies
Cardiovascular Function and Risk Factors
Linh‐Chi Ho
Arkansas State University
Drug-Induced Hepatotoxicity and Protection
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
R. Eric Davis
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Disease Mechanisms Research
Lymphoma Diagnosis and Treatment
Hui‐Ming Chang
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Disease Mechanisms Research
Pharmacological Effects and Toxicity Studies